High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$5.4M
$5,394,335
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
APLS
S
Apellis Pharmaceuticals, Inc.
DeLong Mark Jeffrey
• Officer • Chief Business & Strat Officer
Sell to Cover
2026-02-11
$8,153
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • Chief Business & Strat Officer
Sell to Cover
|
2026-02-11 | $8,153 | S | Form 4 |
| APLS |
Apellis Pharmaceuticals, Inc.
|
CEO
Other
|
2026-02-03 | $33,238 | M | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Chopas James George
• Officer • VP/Chief Accounting Officer
Sell to Cover
2026-01-22
$44,924
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • VP/Chief Accounting Officer
Sell to Cover
|
2026-01-22 | $44,924 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
DeLong Mark Jeffrey
• Officer • Chief Business & Strat Officer
Sell to Cover
2026-01-22
$73,371
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • Chief Business & Strat Officer
Sell to Cover
|
2026-01-22 | $73,371 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Deschatelets Pascal
• Officer • Chief Scientific Officer
Sell to Cover
2026-01-22
$129,025
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • Chief Scientific Officer
Sell to Cover
|
2026-01-22 | $129,025 | S | Form 4 |
| APLS |
Apellis Pharmaceuticals, Inc.
|
CEO
Sell to Cover
|
2026-01-22 | $591,845 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Nicholson Nur
• Officer • Chief Technical Officer
Sell to Cover
2026-01-22
$168,138
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • Chief Technical Officer
Sell to Cover
|
2026-01-22 | $168,138 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Watson David O.
• Officer • General Counsel
Sell to Cover
2026-01-22
$170,467
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • General Counsel
Sell to Cover
|
2026-01-22 | $170,467 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Sullivan Timothy Eugene
• CFO
Sell to Cover
2026-01-22
$223,901
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
CFO
Sell to Cover
|
2026-01-22 | $223,901 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Baumal Caroline
• Officer • Chief Medical Officer
Sell to Cover
2026-01-22
$60,878
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • Chief Medical Officer
Sell to Cover
|
2026-01-22 | $60,878 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Nicholson Nur
• Officer • Chief Technical Officer
Sell to Cover
2026-01-20
$43,604
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • Chief Technical Officer
Sell to Cover
|
2026-01-20 | $43,604 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Watson David O.
• Officer • General Counsel
Sell to Cover
2026-01-20
$48,987
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • General Counsel
Sell to Cover
|
2026-01-20 | $48,987 | S | Form 4 |
| APLS |
Apellis Pharmaceuticals, Inc.
|
CFO
Sell to Cover
|
2026-01-20 | $57,241 | S | Form 4 |
| APLS |
Apellis Pharmaceuticals, Inc.
|
CEO
Sell to Cover
|
2026-01-20 | $161,946 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Deschatelets Pascal
• Officer • Chief Scientific Officer
Sell to Cover
2026-01-20
$17,992
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • Chief Scientific Officer
Sell to Cover
|
2026-01-20 | $17,992 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
DeLong Mark Jeffrey
• Officer • Chief Business & Strat Officer
Sell to Cover
2026-01-20
$26,404
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • Chief Business & Strat Officer
Sell to Cover
|
2026-01-20 | $26,404 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Chopas James George
• Officer • VP/Chief Accounting Officer
Sell to Cover
2026-01-20
$14,370
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • VP/Chief Accounting Officer
Sell to Cover
|
2026-01-20 | $14,370 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Baumal Caroline
• Officer • Chief Medical Officer
Sell to Cover
2026-01-20
$37,250
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • Chief Medical Officer
Sell to Cover
|
2026-01-20 | $37,250 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Deschatelets Pascal
• Officer • Chief Scientific Officer
Sell to Cover
2026-01-13
$50,520
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • Chief Scientific Officer
Sell to Cover
|
2026-01-13 | $50,520 | S | Form 4 |
| APLS |
Apellis Pharmaceuticals, Inc.
|
CEO
Sell to Cover
|
2026-01-13 | $225,999 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Watson David O.
• Officer • General Counsel
Sell to Cover
2026-01-13
$128,242
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • General Counsel
Sell to Cover
|
2026-01-13 | $128,242 | S | Form 4 |
| APLS |
Apellis Pharmaceuticals, Inc.
|
CFO
Sell to Cover
|
2026-01-13 | $85,554 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Nicholson Nur
• Officer • Chief Technical Officer
Sell to Cover
2026-01-13
$58,086
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • Chief Technical Officer
Sell to Cover
|
2026-01-13 | $58,086 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Chopas James George
• Officer • VP/Chief Accounting Officer
Sell to Cover
2026-01-13
$19,369
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • VP/Chief Accounting Officer
Sell to Cover
|
2026-01-13 | $19,369 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
DeLong Mark Jeffrey
• Officer • Chief Business & Strat Officer
Sell to Cover
2026-01-13
$39,493
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • Chief Business & Strat Officer
Sell to Cover
|
2026-01-13 | $39,493 | S | Form 4 |
|
APLS
M
Apellis Pharmaceuticals, Inc.
Watson David O.
• Officer • General Counsel
Other
2026-01-07
$13,276
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • General Counsel
Other
|
2026-01-07 | $13,276 | M | Form 4 |
|
APLS
M
Apellis Pharmaceuticals, Inc.
Watson David O.
• Officer • General Counsel
Equity Compensation
2026-01-07
$0
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • General Counsel
Equity Compensation
|
2026-01-07 | $0 | M | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Watson David O.
• Officer • General Counsel
10b5-1 Sell
2025-12-16
$122,450
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • General Counsel
10b5-1 Sell
|
2025-12-16 | $122,450 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Watson David O.
• Officer • General Counsel
10b5-1 Sell
2025-11-17
$100,300
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • General Counsel
10b5-1 Sell
|
2025-11-17 | $100,300 | S | Form 4 |
| APLS |
Apellis Pharmaceuticals, Inc.
|
CFO
Other
|
2025-10-21 | $100,300 | M | Form 4 |
| APLS |
Apellis Pharmaceuticals, Inc.
|
CFO
10b5-1 Sell
|
2025-10-21 | $280,300 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Watson David O.
• Officer • General Counsel
10b5-1 Sell
2025-10-16
$126,100
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • General Counsel
10b5-1 Sell
|
2025-10-16 | $126,100 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Dunlop A. Sinclair
• Director
10b5-1 SellΔOwn -89.0%
2025-10-10
$737,536
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Director
10b5-1 SellΔOwn -89.0%
|
2025-10-10 | $737,536 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Dunlop A. Sinclair
• Director
10b5-1 SellΔOwn -47.8%
2025-09-30
$702,057
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Director
10b5-1 SellΔOwn -47.8%
|
2025-09-30 | $702,057 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Dunlop A. Sinclair
• Director
10b5-1 SellΔOwn -31.1%
2025-09-19
$713,561
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Director
10b5-1 SellΔOwn -31.1%
|
2025-09-19 | $713,561 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Watson David O.
• Officer • General Counsel
10b5-1 Sell
2025-09-16
$121,700
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • General Counsel
10b5-1 Sell
|
2025-09-16 | $121,700 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
Chopas James George
• Officer • VP/Chief Accounting Officer
Sell to Cover
2025-09-15
$4,572
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • VP/Chief Accounting Officer
Sell to Cover
|
2025-09-15 | $4,572 | S | Form 4 |